Rheumatology Advance Access originally published online on May 23, 2007
Rheumatology 2007 46(8):1372-1374; doi:10.1093/rheumatology/kem056a
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2007. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Gout
Rheumatology Department, Princess Royal Hospital, Brighton and Sussex University Hospitals Trust, 1Renal Department, Guy's, King's & St Thomas’ School of Medicine, London, 2Rheumatology Department, Derbyshire Royal Infirmary and Derbyshire County Primary Care Trust, 3Academic Rheumatology Unit, University of Nottingham, 4The Queen's Medical Research Institute and Endocrinology Unit, University of Edinburgh, 5Centre for Clinical Pharmacology and Therapeutics, University College Hospital, London, 6UK Gout Society, and 7The Queen's Medical Research Institute and Rheumatic Diseases Unit, University of Edinburgh, UK.
Correspondence to: Prof. George Nuki, Emeritus Professor of Rheumatology, University of Edinburgh Osteoarticular Research Group, The Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, UK. E-mail: g.nuki@ed.ac.uk
KEY WORDS: Gout, Guidelines, Non-pharmacological treatment, Pharmacological treatment
| The first 10% of the full text of this article appears below. |
 |
Scope and purpose of the guideline |
|---|
Gout is a common disease both in primary care and hospital practice [1].
Although drug therapy for gout has become a paradigm for the effective management and prevention of an acute and potentially chronic rheumatic disease, many of the recommendations for treatment are based on expert consensus rather than research evidence and audits of practice suggest that treatment is very variable.
Evidence-based guidelines are needed at the present time:
- to provide a framework for improving standards of care.
- to assess the potential of new therapies such as Coxibs [2], urate oxidases [3] and novel xanthine oxidase inhibitors [4] currently in clinical development;
- to provide recommendations for
. . . [Full Text of this Article]
|
Guideline for the management of gout |
|---|
Management of acute gout
Recommendations for diet, lifestyle modification and non-pharmacological modalities of therapy
Management of recurrent, intercritical and chronic gout
|
Recommendations for audit |
|---|
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. L. Riches, A. F. Wright, and S. H. Ralston Recent insights into the pathogenesis of hyperuricaemia and gout Hum. Mol. Genet., October 15, 2009; 18(R2): R177 - R184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. G. Rider and K. M. Jordan The modern management of gout Rheumatology, October 5, 2009; (2009) kep306v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Doherty New insights into the epidemiology of gout Rheumatology, May 1, 2009; 48(suppl_2): ii2 - ii8. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Perez-Ruiz Treating to target: a strategy to cure gout Rheumatology, May 1, 2009; 48(suppl_2): ii9 - ii14. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. L. Edwards Febuxostat: a new treatment for hyperuricaemia in gout Rheumatology, May 1, 2009; 48(suppl_2): ii15 - ii19. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 EMQ EMQ answers Emerg. Med. J., April 1, 2008; 25(4): 245 - 245. [Full Text] [PDF]
|
|